Sánchez-de-Castro M., et al.
16. Baeten JM, Palanee-Phillips T, et al. Use of a Vaginal Ring Containing Da-pivirine
for HIV-1 Prevention in Women. N Engl J Med. 2016 Dec 1; 375(22):
2121-2132. doi: 10.1056/NEJMoa1506110. Epub 2016 Feb 22. PMID:
26900902; PMCID: PMC4993693.
17. Nel A, van Niekerk et al.Safety and Efficacy of a Dapivirine Vaginal Ring for
HIV Prevention in Women. N Engl J Med. 2016 Dec 1; 375(22): 2133-2143.
doi: 10.1056/NEJMoa1602046. PMID: 27959766.
18. European Medicines Agency. Human medicine European public assessment
report (EPAR) Jyseleca®. Consultado el 23/11/2020. Disponible en: https://
www.ema.europa.eu/en/documents/product-information/jyseleca-epar-pro-duct-
information_es.pdf.
19. Combe, B. et al. Efficacy and safety of Filgotinib for patients with rheuma-toid
arthritis with inadequate response to methotrexate: FINCH 1 52-week
results. Abstract ACR/ARP Annual Meeting 2019.
20. Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of Filgotinib vs Pla-cebo
on Clinical Response in Patients With Moderate to Severe Rheumatoid
Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy:
The FINCH 2 Randomized Clinical Trial. JAMA. 2019 Jul 23; 322(4): 315-
325. doi: 10.1001/jama.2019.9055. Erratum in: JAMA. 2020 Feb 4; 323(5):
480. PMID: 31334793; PMCID: PMC6652745.
21. Westhovens R, Rigby W, et al. Safety of Filgotinib for Patients with Rheu-matoid
Arthritis Naïve to Methotrexate Therapy: FINCH3 Primary Outco-me
Results abstract. Annals of the Rheumatic Diseases. 2019; 78: 259-261.
NCT02886728.
22. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Bo-letín
mensual julio 2020. Disponible en: https://www.aemps.gob.es/informa/
boletines-aemps/boletinMensual/2020-3/boletin-mensual-de-la-aemps-so-bre-
medicamentos-de-uso-humano-del-mes-de-septiembre-de-2020/.
23. Baccarini CI, Simon MW, Brandon D, Christensen S, Jordanov E, Dhingra
MS. Safety and Immunogenicity of a Quadrivalent Meningococcal Conju-gate
Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age:
244 Sanid. mil. 2020; 76 (4)
A Phase III, Randomized Study. Pediatr Infect Dis J. 2020 Oct; 39(10):
955-960. doi: 10.1097/INF.0000000000002832. PMID: 32852352; PMCID:
PMC7497415.
24. Chang LJ, Hedrick J, Christensen S, Pan J, Jordanov E, Dhingra MS. A
Phase II, randomized, immunogenicity and safety study of a quadrivalent
meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in
the United States. Vaccine. 2020 Apr 23; 38(19): 3560-3569. doi: 10.1016/j.
vaccine.2020.03.017. Epub 2020 Mar 21. PMID: 32209248.
25. Dhingra MS, Peterson J, Hedrick J, Pan J, Neveu D, Jordanov E. Immunoge-nicity,
safety and inter-lot consistency of a meningococcal conjugate vaccine
(MenACYW-TT) in adolescents and adults: A Phase III randomized study.
Vaccine. 2020 Jul 14; 38(33): 5194-5201. doi: 10.1016/j.vaccine.2020.06.013.
Epub 2020 Jun 19. PMID: 32565344.
26. Nagy CF, Leach TS, Hoffman JH, Czech A, Carpenter SE, Guttendorf R.
Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy
Volunteer Studies. Clin Ther. 2016 Sep; 38(9): 2083-2097.e7. doi: 10.1016/j.
clinthera.2016.07.170. Epub 2016 Aug 24. PMID: 27568215.
27. Nagy CF, Leach TS, King A, Guttendorf R. Safety, Pharmacokinetics, and
Immunogenicity of Obiltoxaximab After Intramuscular Administration
to Healthy Humans. Clin Pharmacol Drug Dev. 2018 Aug; 7(6): 652-660.
doi: 10.1002/cpdd.410. Epub 2017 Nov 10. PMID: 29125719; PMCID:
PMC6668011.
28. Dunkle LM, Izikson R, Patriarca P, Goldenthal KL, Muse D, Callahan J,
Cox MMJ; PSC12 Study Team. Efficacy of Recombinant Influenza Vaccine
in Adults 50 Years of Age or Older. N Engl J Med. 2017 Jun 22; 376(25):
2427-2436. doi: 10.1056/NEJMoa1608862. PMID: 28636855.
29. Dunkle LM, Izikson R, Patriarca PA, Goldenthal KL, Muse D, Cox MMJ.
Randomized Comparison of Immunogenicity and Safety of Quadrivalent
Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49
Years of Age. J Infect Dis. 2017 Dec 5; 216(10): 1219-1226. doi: 10.1093/
infdis/jix478. PMID: 28968871.